Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half Dose vs Full Dose TIV Influenza Vaccine
NCT00283283Phase 2Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Nov 2004
- Primary completion
- Nov 2004
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Fluzone Trivalent in influenza (8 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Immune Response: Age 18-49 at 21 days and Immune Response: Age 50-64 at 21 days. Started Nov 2004; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00283283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00283283.